The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.50
Bid: 63.00
Ask: 66.00
Change: 1.00 (1.57%)
Spread: 3.00 (4.762%)
Open: 63.00
High: 66.50
Low: 61.50
Prev. Close: 63.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMV C leads £4.2m round in 5G and SATCOM leader

29 Nov 2022 07:00

RNS Number : 8492H
NetScientific PLC
29 November 2022
 

Reach: 07.00, 29 November 2022

 

NetScientific plc

 

("NetScientific" or the "Company")

 

EMV Capital leads £4.2m investment round in Scottish 5G and SATCOM leader

 

Sofant Technologies also announces contract with Fortune Global 500 defence company

 

London, UK - 29 November 2022: NetScientific plc (AIM: NSCI), the active international holding company which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, announces that it has joined an investment round led by its subsidiary EMV Capital Ltd ("EMVC"), together with Scottish Enterprise, Kelvin Capital Limited, and The Future Fund, in Edinburgh based Sofant Technologies Ltd ("Sofant"). The final close took the total joint investment round to £4.2m. This utilises the Company's capital light investment model, including c. £0.3m of investment from NetScientific through convertible loans converting at a discount into this round, and £1.6m of investment from investors introduced by EMVC, including both direct equity and convertible loans.

 

Sofant has also announced a contract with a Fortune Global 500 defence company to support the development of a next-generation tactical communication system.

 

Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications during the first half of 2023, and with commercial sales expected to begin later in the year. During the past year, Sofant has doubled the size of its team and achieved several significant technical and commercial milestones which have cleared the pathway to market.

 

Sofant is building a proprietary, highly efficient radio platform that directly addresses the most difficult challenges facing future wireless communication systems. While Sofant is targeting satellite communications and terrestrial fifth-generation (5G) telecommunications where power consumption is reduced by more than 70%, it has now also demonstrated the relevance of its technology to national security applications.

 

Dr Ilian Iliev, CEO of NetScientific and Sofant Board member, said that:

 

"We are delighted with Sofant's tremendous progress in their development roadmap. They continue to make a key contribution to the UK's space tech and telecoms sectors by developing a key component for increased resilience and energy efficiency in SatComs and other telecommunications systems.

 

"We also congratulate Sofant on their first commercial agreement with a leading defence contractor, as global awareness of the critical importance of communications to national security increases. We expect Sofant to play a significant role in future communication systems and are very pleased that its value is already recognised by industry leaders."

 

David Wither, CEO of Sofant, added:

 

"We are very pleased to have investors who understand the disruptive nature of Sofant's technology. When Sofant closed the previous funding round we told our investors we would demonstrate our core technology, which occurred in June of 2022. Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications, with commercial sales expected to begin later in the year."

 

This investment will result in the direct equity holding in Sofant by NetScientific of 1.8% at an aggregate value of £0.4m based on this funding round, in addition to EMVC's Capital Under Advisory representing 27.2%.

 

-Ends-

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6864

Email: langus@belvederepr.com

 

About NetScientific

 

NetScientific Plc ("NSCI") is an active holding Company that proactively invests in a global portfolio of companies across the healthcare, life science, ESG, and deep technology sectors. NetScientific delivers shareholder returns through a proactive and hands-on management approach to its portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong Trans-Atlantic and growing international presence, providing attractive expansion prospects.

 

The Company differentiates itself by employing a capital-light investment approach, making use of its wholly owned subsidiary, EMV Capital's network of private, corporate, and institutional investors. By syndicating investment and making minimal use of its balance sheet, the Company is able to secure direct stakes, as well as carried interest stakes, in its portfolio. This ultimately creates a structure that can support a large portfolio with a limited balance sheet.

 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

 

www.netscientific.net

 

About Sofant Technologies

 

Sofant Technologies is a leading-edge radio technology company based in Edinburgh, Scotland. The company is applying its proprietary RF MEMS technology to develop an extremely low power, low-cost platform which solves power consumption and heat problems in satellite communications and 5G antenna systems. Sofant employs a fabless semiconductor business model which enables it to leverage long established high-volume, low-cost production methods. This positions Sofant to offer its customers game-changing performance at a highly competitive price and guaranteed scalability.

 

www.sofant.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFLLLFLTFIF
Date   Source Headline
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
21st Dec 201811:04 amRNSForm 8.5 - NetScientific PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.